Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015

February 19, 2015

GAITHERSBURG, Md., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its fourth quarter and full year 2014 financial and operating results after the close of U.S. financial markets on Thursday, February 26, 2015.

In addition, management will host a conference call to discuss the quarterly and year-end financial results and provide an update on corporate activities.

Conference call details are as follows:

Date: February 26, 2015

Time: 4:30 pm US Eastern Time

Dial-in number: (877) 212-6076 (Domestic) or (707) 287–9331 (International)

Via web: www.novavax.com

Conference call replay:

Dates: Starting at 6:31 pm ET on February 26, 2015 until midnight March 5, 2015

Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)

Passcode: 89629680

Via web: www.novavax.com, "Investor Info"/"Events"

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-MTM adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.

CONTACT: Barclay A. Phillips

SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.

Senior Manager, Investor Relations

240-268-2000

ir@novavax.comNovavax, Inc.David Schull or Todd Davenport, Ph.D.

Russo Partners, LLC

212-845-4271

david.schull@russopartnersllc.comtodd.davenport@russopartnersllc.com